Amneal Pharmaceuticals has immediately launched upon approval the first generic alternative to Merck & Co’s NuvaRing (etonogestrel/ethinylestradiol) vaginal ring. In securing US Food and Drug Administration approval for its EluRyng branded generic, the US generics specialist has outpaced many of its peers that are also targeting NuvaRing as part of strategies to pursue complex generics.
Approved as an abbreviated new drug application, EluRyng vaginal ring, delivering 0.12mg of etonogestrel and 0